[Hypertensive therapy with prazosin. Concomitant cardiovascular, metabolic and respiratory diseases. Proven facts and potential aspects].
Prazosin sinks the pathologically increased blood pressure, reduces pre- and afterload in myovascular insufficiency and has an interesting influence on plasma lipid fractions with regard to the coronary risk. Prazosin thus intervenes in the three cardiovascular disease processes, which often exist simultaneously, which are mutually caused. Studies which have taken place in the meantime demonstrate the possibilities of Prazosin as a treatment for Raynaud's disease and gangrene. The relatively long bio-availability of the preparation led constantly to the discovery of additional ranges of application, but did not deliver any new findings which would have made restrictions of the original application necessary. On the contrary, Prazosin proved to be especially favourable and capable of being universally applied in the illnesses which frequently accompany hypertension and cardiac insufficiency.
D000293:Adolescent; D000328:Adult; D001145:Arrhythmias, Cardiac / Q000188:drug therapy; D002318:Cardiovascular Diseases / Q000150:complications; D048909:Diabetes Complications; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D007668:Kidney / Q000187:drug effects; D008055:Lipids / Q000097:blood; D009203:Myocardial Infarction / Q000188:drug therapy; D011224:Prazosin / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*; D012140:Respiratory Tract Diseases / Q000188:drug therapy
D008055:Lipids; D011799:Quinazolines; D011224:Prazosin
Hypertonie-Therapie mit Prazosin. Kardiovaskuläre, metabolische und respiratorische Begleiterkrankungen. Gesicherte Erkenntnisse und potentielle Aspekte.